Company news

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) news

Every Corbus Pharmaceuticals Holdings, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) news

Press releases & updates

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals to Host Conference Call to Discuss Topline Data from CANYON-1 Clinical Trial and the Potential of CRB-913 In Obesity

Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Corbus Pharmaceuticals Announces Last Patient Last Visit in CANYON-1 Study of CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Announces FDA Clearance to Initiate TEMPO-1 Registrational Study of CRB-701 in Patients with 2L Oropharyngeal Cancer

Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer

Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Can...

Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data C...

Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026

Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701

Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer

Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit

Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstratin...

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursda...

Corbus Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals Announces Proposed Public Offering

Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals to Present CRB-701 Phase 1/2 Data at ESMO 2025

Corbus Pharmaceuticals to Participate in the Upcoming Piper Sandler Virtual Oncology Symposium

Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals’ Nectin-4 Targeting ADC CRB-701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for its Nectin-4 Targeting ADC CRB-701 a...

Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist C...

Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab

Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium

Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Corbus Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Tre...

Corbus Pharmaceuticals Reports Q4 and 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (...

Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung

Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update